Taevas
United StatesMedical Devices
Legal Representation
Legal Representation for Medical Devices in United States
Foreign medical device manufacturers entering the United States must designate a US Agent and navigate complex FDA regulatory pathways. Taevas Global provides authoritative legal representation that keeps your submissions compliant, your timelines on trac
Market
United States
Industry
Medical Devices
Service
Legal Representation
Regulator
FDA Center for Devices and Radiological Health (CDRH)
Timeline
4-8 weeks to active representation
What We Deliver
Six Pillars of United States Medical Devices Intelligence
Our legal representation framework spans every critical dimension of FDA compliance, market access, and ongoing regulatory stewardship for medical device companies entering or operating in the United States.
01
FDA US Agent Designation
Every foreign medical device establishment registered with the FDA must appoint a US Agent who serves as the official point of contact for all regulatory communications. Taevas Global fulfills this mandatory role, ensuring your establishment registration under 21 CFR Part 807 is continuously maintained and all FDA correspondence is handled promptly and accurately.
Mandatory US Agent appointment under 21 CFR 807.40
24-hour FDA communication response capability
Annual establishment registration renewal management
How It Works
From Brief to Board-Ready Intelligence
Our four-step engagement model moves your medical device company from initial scoping through active FDA-compliant legal representation with full transparency at every stage.
Step 1 · Day 1-2
Regulatory Scoping and Device Assessment
We begin with a structured intake to understand your device, intended use, target market, and current regulatory status. Our team reviews existing technical documentation, prior regulatory submissions, and quality system records to identify gaps and define the scope of legal representation required.
Taevas Approach
This phase produces a written Regulatory Scoping Memo that documents your device classification, applicable FDA regulations, identified compliance gaps, and a prioritized action plan. The memo serves as the foundation for your FDA engagement strategy and is shared with your internal regulatory and legal teams before any work proceeds.
Market Snapshot
United States Medical Devices Market at a Glance
$0B
US Medical Devices Market Size (2024)
0%
Projected Annual Market Growth Rate
0+
FDA-Registered Device Manufacturers
0+
510(k) Decisions Issued Annually by FDA
Largest Medical Device Market Globally
The United States represents approximately 40 percent of the global medical devices market, making it the single most important commercial destination for device manufacturers worldwide. The market is driven by a sophisticated healthcare infrastructure, high per-capita healthcare spending, and rapid adoption of innovative technologies across hospitals, ambulatory surgical centers, and home care settings.
FDA CDRH Oversight and Enforcement
The FDA's Center for Devices and Radiological Health regulates over 190,000 different device types across 16 medical specialties. CDRH has significantly increased its enforcement activity in recent years, with a growing number of Warning Letters, import alerts, and mandatory recalls issued annually. Foreign manufacturers without proper US legal representation face heightened risk of import detention and market exclusion.
Innovation and Digital Health Surge
The United States is the global leader in medical device innovation, with digital health, AI-enabled devices, and combination products representing the fastest-growing regulatory categories. The FDA has issued multiple new guidance documents covering Software as a Medical Device (SaMD), AI and machine learning-based devices, and cybersecurity requirements, creating new compliance obligations for manufacturers of connected and software-driven devices.
QMSR Transition and Regulatory Modernization
The FDA finalized the Quality Management System Regulation (QMSR) in February 2024, aligning US quality system requirements more closely with ISO 13485:2016 and becoming effective in February 2026. This transition represents the most significant change to US device quality regulation in nearly three decades and requires manufacturers to review and update their quality systems, procedures, and documentation to maintain compliance.
What's Included
Everything in Your Representation Package
Every Taevas Global Legal Representation engagement for Medical Devices in the United States delivers eight core components designed to establish, maintain, and protect your FDA-compliant market presence.
Regulatory Scoping Memo
A written assessment of your device classification, applicable FDA regulations, compliance gaps, and prioritized action plan delivered at engagement launch.
FDA US Agent Agreement and Certificate
Formal execution of the US Agent designation with a certificate of representation suitable for FDA submission and establishment registration purposes.
Establishment Registration and Device Listing Management
Complete management of your FDA FURLS establishment registration and all device listings, including annual renewals and updates for new product configurations.
Regulatory Pathway Strategy Report
A detailed written strategy document identifying the optimal FDA clearance or approval pathway for each device, including predicate analysis and timeline projections.
Submission Preparation and Filing
Drafting, review, and FDA submission of 510(k) notifications, De Novo requests, PMA applications, or Q-Submissions as specified in the engagement scope.
FDA Correspondence and AI Response Management
Handling of all FDA communications including Additional Information requests, deficiency letters, and interactive review correspondence throughout the submission lifecycle.
Post-Market Compliance Calendar
A customized compliance calendar tracking all recurring FDA obligations including MDR reporting deadlines, registration renewals, post-market study milestones, and labeling review schedules.
Quarterly Regulatory Intelligence Briefing
A quarterly report covering FDA guidance updates, enforcement trends, competitive clearance activity, and regulatory changes relevant to your specific device category and market segment.
Who This Is For
Built for These Situations
Market Entry
Foreign Manufacturer Entering the US Market
Your company has developed a medical device with CE marking or other international approvals and is now targeting the United States as your next major market. You need a mandatory US Agent designation, an FDA establishment registration, and a clear regulatory pathway strategy to achieve 510(k) clearance or PMA approval without costly delays or compliance missteps.
Outcome
Achieve FDA-compliant US market entry with an active establishment registration, designated US Agent, and a submitted clearance application within your planned commercial launch timeline.
Next Steps
After Legal Representation, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your United States Opportunity?
Taevas Global's legal representation team is ready to establish your FDA-compliant presence in the United States market. Contact us today for a no-obligation consultation and let us build your path to US market access.
Mandatory FDA US Agent designation fulfilled on day one
Expert regulatory pathway strategy for faster 510(k) or PMA clearance
Full post-market compliance coverage including MDR and annual renewals
Dedicated legal counsel for enforcement response and inspection support